Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2007 December;51(4) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2007 December;51(4):297-303

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413


eTOC

 

REVIEWS  ADVANCES IN RADIOIMMUNOIMAGING AND RADIOIMMUNOTHERAPY


The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2007 December;51(4):297-303

language: English

Estimation of metastatic cure after radionuclide therapy

Bernhardt P., Forssell-Aronsson E.

Department of Radiation Physics Göteborg University, Sahlgrenska University Hospital Göteborg, Sweden


FULL TEXT  


argeted radionuclide therapy of disseminated tumor disease involves many factors that will affect the therapeutic outcome. For optimization of such therapy, it is important to know how these factors affect the therapeutic outcome. In this paper, the metastatic cure probability (MCP) model is described. The MCP model is a valuable tool for analyses of the various factors influencing the metastatic cure. The factors discussed are: 1) the physical parameters (the energy and range of emitted particles, absorbed dose-distributions, and cross-irradiation of tumors from the surrounding normal tissue) and 2) the biological parameters (radiosensitivity of tumors, tumor distributions, tumor growth rate, metastasis formation rate, variable tumor activity concentration and non-homogeneous tumor activity distributions).

top of page

Publication History

Cite this article as

Corresponding author e-mail